La cadena de opciones muestra datos clave de las opciones de acciones de Zhengye Biotechnology a varios precios de ejercicio y fechas de vencimiento. Los operadores utilizan esta información para analizar posibles operaciones y evaluar el sentimiento del mercado para Zhengye Biotechnology..

Zhengye Biotechnology (NASDAQ:ZYBT) Bolsa, Cadena de Opciones

Zhengye Biotechnology Holding Ltd is engaged in research, development, manufacturing and sales of veterinary vaccines, with an emphasis on vaccines for livestock. It has diverse range of vaccines, including vaccines for swine, cattle, goats, sheep, poultry, and dogs and is available in 29 provincial regions across China and are exported overseas to Vietnam, Pakistan and Egypt.

GameStop Corp.

News

Pre-Market Outlook

Markets

Movers

Trading Ideas

BHIL

BSGM

CISO

CLEU

GDHG

HUMA

IMTE

NYXH

ORKA

PTPI

RAPP

SURG

THTX

TXMD

WINT

ZYBT

El premercado de hoy revela fuertes movimientos bursátiles tras informes financieros y aprobaciones clave en sectores críticos.

Las acciones de GameStop (GME) suben alrededor del 13%; Aquí están 20 acciones que se mueven en el premercado

Zhengye Biotechnology Holding Limited - Ordinary Shares

Zhengye Biotechnology Holding Ltd

Shares of tech companies soared following President Donald Trump's announcement that he will place a 90-day pause on tariffs for countries that have not retaliated against U.S. trade measures. Markets rose on the news, driven<a href="https://www.benzinga.com/25/04/44720006/markets-take-off-as-trump-announces-90-day-tariff-pause-for-non-retaliating-nations-slaps-china-with-125-duty"> higher by tech stocks. </a>
The Details: Technology was the top performing sector in the S&amp;P 500 on Wednesday with the Technology SPDR Select Sector Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLK#NYSE">XLK</a>) gaining 13.43% in the session. Microsoft Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MSFT#NASDAQ">MSFT</a>), the fund's largest holding, rose 10.13% and its second-largest holding, Apple, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AAPL#NASDAQ">AAPL</a>), climbed 15.33% in its best one-day performance since 1998. 
Read Next: <a href="https://www.benzinga.com/25/04/44695907/elon-musk-calls-trump-trade-advisor-peter-navarro-dumber-than-sack-of-bricks-defends-tesla-as-the-most-american-made-cars">Elon Musk Calls Trump Trade Advisor Peter Navarro &#8216;Dumber Than Sack Of Bricks,&#8217; Defends Tesla As &#8216;Most American-Made Cars&#8217;&nbsp;</a>
The sector's top two gainers were both chip stocks, with Microchip Technology, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>) up 27.05% and Advanced Micro Devices, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMD#NASDAQ">AMD</a>), which gained 23.82% in the tech-fueled rally. 
Other notable gainers in the sector include Palantir Technologies, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PLTR#NASDAQ">PLTR</a>), which rose 19% and NVIDIA Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NVDA#NASDAQ">NVDA</a>), which climbed 18.72% in the session. 
Expert Ideas: Wedbush tech analyst Dan Ives said that<a href="https://www.benzinga.com/analyst-ratings/analyst-color/25/04/44721874/trumps-tariff-pause-saves-market-from-edge-of-the-cliff-dan-ives-says-biggest-wild-card-still-remains"> he expects</a> "massive negotiations" to start to pick up and noted China remains the "biggest wild card" for markets.&nbsp;
"For tech stocks, this was much-needed relief and pulls stocks and the market from the edge of the cliff, although China remains the biggest X variable related to Apple and the broader supply chain," Ives said.
Markets <a href="https://www.benzinga.com/economics/macro-economic-events/25/04/44720903/nasdaq-100-eyes-strongest-day-since-2008-as-magnificent-seven-add-15-trillion-in-historic-market-rally">shot higher</a> following Trump's announcement, with the tech-heavy Nasdaq 100 posting its best day since January 2001. 
"The market's move upward is violent, and speaks to how badly the market was looking for clarity on this issue," said Chris Brigati, chief investment officer at SWBC.&nbsp;
Read Next:&nbsp;
<ul>
<li><a href="https://www.benzinga.com/news/large-cap/25/03/44537429/cathie-wood-doubles-down-on-2600-tesla-stock-price-prediction">Cathie Wood Doubles Down On $2,600 Tesla Stock Price Prediction</a></li>
</ul>
Photo: Shutterstock

Large Cap

Sector ETFs

Tech

ETFs

AAPL

MCHP

MSFT

NVDA

PLTR

Technology Stocks Outperform After Trump's Tariff Pause: Microchip Technology, AMD Lead Sector Higher

Nearly three decades after her passing, Princess Diana's legacy continues to captivate collectors worldwide. On June 26, <a href="https://www.juliensauctions.com/en">Julien's Auctions</a> will host "Princess Diana's Style and a Royal Collection" at the Peninsula Beverly Hills, <a href="https://www.vanityfair.com/style/story/princess-diana-wardrobe-auction?utm_source=nl&amp;utm_brand=vf&amp;utm_mailing=VF_CH_040925&amp;utm_medium=email&amp;bxid=65f99495919a8e1ac2043278&amp;cndid=76750232&amp;hasha=f9aacf9e140c558cf2966f87d3f9090d&amp;hashb=08b5506c634fa4e50453b830301e29884b06756c&amp;hashc=e846c2d8e9b4b53fcb933dfe60dd619a3c6bc2c0df29c6abdaf5307dd3ff1646&amp;esrc=MARTECH_ORDERFORM&amp;mbid=mbid%3DCRMVYF012019&amp;source=EDT_VYF_NEWSLETTER_0_COCKTAIL_HOUR_ZZ&amp;utm_campaign=VF_CH_040925&amp;utm_term=VYF_Cocktail_Hour">according </a>to Vanity Fair, featuring more than 200 items spanning royal history — from Diana herself to Queen Elizabeth II, the Queen Mother, and the Duke and Duchess of Windsor. 
The centerpiece? A curated collection of Diana's clothing and personal items, some originally sold at her famous 1997 Christie's auction — a fundraiser she called a "fresh start" following her divorce. That event raised over $3 million for the AIDS Crisis Trust and the Royal Marsden Hospital's Cancer Fund. 
The auction on June 26 follows two consecutive years of record-breaking sales, including the 2023 auction of a&nbsp;1985 evening gown by Jacques Azagury&nbsp;that fetched $1.14 million, and the 2024 sale of a&nbsp;1987 Victor Edelstein evening gown&nbsp;for $910,000, along with several other dresses commanding six-figure prices, says Julien&#8217;s Auctions.
Julien's Auctions co-founder Martin Nolan attributes this continued fascination to Diana's timeless elegance and her carefully cultivated image. "She knew how to dress and read the room," he says.
Among the standout pieces in this auction is her 1989 Bellville Sassoon "caring dress," a colorful floral day dress worn during hospital visits with children. Another highlight: a cocktail dress symbolizing her post-divorce independence — a nod to her infamous "revenge dress."
Also included are Diana's handwritten notes, along with fashion from other royals. Queen Elizabeth II and the Queen Mother are represented by their signature bright ensembles, while the Duke and Duchess of Windsor offer a glimpse into high fashion.
Before the Beverly Hills auction, the collection will tour globally, stopping at the Museum of Pop Culture in Seattle, Ireland's Museum of Style Icons, and a London venue. For fans, it's a chance to view — and perhaps own — a piece of royal history that continues to resonate across generations.
A portion of the auction proceeds will benefit Muscular Dystrophy UK, <a href="https://www.juliensauctions.com/en/articles/the-crown-jewel-of-couture-princess-diana-s-largest-wardrobe-auction-ever-announced-at-julien-s">says</a> Julien&#8217;s Auctions in a press release.
Read Next: • <a href="https://www.benzinga.com/personal-finance/25/04/44725488/shaq-says-he-wont-hand-everything-to-his-6-kids-on-a-platter-just-because-hes-super-rich-let-them-live-a-life-of-trials-and-tribulations">Shaq Says He Won&#8217;t Hand Everything to His 6 Kids &#8216;On A Platter&#8217; Just Because He&#8217;s Super Rich —&#8217;Let Them Live a Life of Trials and Tribulations&#8217;</a>
Photo: <a href="https://www.shutterstock.com/g/mark+reinstein">mark reinstein</a> via Shutterstock

Entertainment

Princess Diana's Iconic Style Heads To Auction Block

BBB Foods (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/TBBB#NYSE">TBBB</a>) reported quarterly losses of $(0.001) per share. The company reported quarterly sales of $814.60 million which beat the analyst consensus estimate of $810.71 million by 0.48 percent.

Earnings

TBBB

BBB Foods Q4 EPS $(0.001), Sales $814.60M Beat $810.71M Estimate

Shaquille O'Neal might be worth half a billion dollars, but don't expect his six kids to be coasting on that wealth anytime soon.
"I like to let them live a life of trials and tribulations," Shaq said on an episode of <a href="https://youtu.be/QyY8FBqkhzk?si=gHvKbswwW8jlhz32">"The Big Podcast" in 2022</a>. "I don't want to always put it on a platter for them." And he meant it. O'Neal—who has built an empire well beyond basketball—makes it clear that being the child of an NBA legend doesn't come with a free ride.
Don't Miss:
<ul>
<li>Inspired by Uber and Airbnb &#8211; Deloitte's fastest-growing software company is transforming 7 billion smartphones into income-generating assets &#8211; <a href="https://www.benzinga.com/money/mode-mobile-2">with $1,000 you can invest at just $0.26/share!</a></li>
<li>Maker of the $60,000 foldable home has 3 factory buildings, 600+ houses built, and big plans to solve housing —<a href="https://www.benzinga.com/money/boxabl"> this is your last chance to become an investor for $0.80 per share.</a></li>
</ul>
At the time of the interview, he was specifically referencing his youngest daughter, Me'arah O'Neal, then 16, who was already drawing attention from college recruiters. Fast forward to the present and she's now 18 and continuing to make her own mark.&nbsp;
While some parents might jump in to micromanage every decision, Shaq prefers to hang back. "They know what I know," he said about his kids navigating college athletics. "I'm here if they need me, but I want them to figure things out for themselves."
Shaq's hands-off-but-there approach isn't just about sports—it's about preparing his children for real life. He's long made it clear that his kids won't inherit his fortune just for being his kids. He expects them to earn their own success. That means college degrees, business plans, and a whole lot of self-motivation.
"If you want me to invest in one of your companies, <a href="https://www.benzinga.com/personal-finance/24/09/40943843/we-aint-rich-im-rich-nba-legend-shaq-says-his-daughters-and-sons-dont-get-equal-treatment-my-boy">you're going to have to present it,</a>" he said on the "Earn Your Leisure" podcast. "I'm not giving you nothing."
Trending: The secret weapon in billionaire investor portfolios that you almost certainly don't own yet. <a href="https://www.benzinga.com/money/masterworks">See which asset class has outpaced the S&amp;P 500 (1995-2024) – and with near-zero correlation.</a>
It's a philosophy rooted in his own story. Shaq didn't come from money. Raised in a military household by a strict stepfather, he grew up with discipline, expectations, and hustle. He didn't just land in success—he <a href="https://www.benzinga.com/personal-finance/25/03/44068159/nba-legend-shaq-says-his-net-worth-quadrupled-once-he-took-note-from-jeff-bezos-and-started-investing-in-things-that-change-peoples-lives">worked for it, earned it, and multiplied it</a>. Post-NBA, he's turned that mindset into a brand—investing in franchises, <a href="https://www.benzinga.com/startups/24/09/40677330/shaq-refused-to-pay-80-000-for-security-and-made-a-surprising-choice-he-invested-in-a-company-bezos">tech companies</a>, and everything from Five Guys to car washes.
Now worth an estimated $500 million to $600 million, he's not just sitting courtside—he's in boardrooms, on panels, and behind business deals. But when it comes to family, Shaq is still all about the fundamentals: work hard, stay grounded, and don't skip the hard stuff.
In his eyes, the "trials and tribulations" aren't just obstacles—they're the training ground. And for Shaq, handing over a perfect life would be missing the whole point.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/money/are-you-rich">Are you rich?</a> Here&#8217;s what Americans think you need to be considered wealthy.</li>
<li><a href="https://www.benzinga.com/money/mark-cubans-advice-for-lotto-winners">Many are surprised by Mark Cuban's advice for lotto winners: Cash or annuity?</a></li>
</ul>

Personal Finance

Shaq Says He Won't Hand Everything to His 6 Kids 'On A Platter' Just Because He's Super Rich  —'Let Them Live a Life of Trials and Tribulations'

As markets wobble, inflation eats at savings, and global instability fuels anxiety, one 65-year-old posed the question that's now echoing across retirement circles: "Is this the worst time to be 65 years old in America?"
The post—shared by a <a href="https://www.reddit.com/r/Retire/s/dhhVFNrEP5">solo business owner in the r/Retire subreddit</a>—wasn't some abstract financial rant. It was personal. "I raised my children on my own for the bulk of their lives and didn't have 2 nickels to rub together until the last few years," the user wrote. "I started saving only in the last 5 or so years." Now, staring down retirement with limited time to catch up, he's watching a volatile economy tighten the screws.
Don't Miss:
<ul>
<li><a href="https://www.benzinga.com/money/vatom-adv">Invest in the Future of Digital Engagement. Own a Piece of the $100 Billion Metaverse Today for Just $500.</a></li>
<li>Hasbro, MGM, and Skechers trust this AI marketing firm — <a href="https://www.benzinga.com/money/rad-intel">invest pre-IPO from $0.55 per share now</a>.</li>
</ul>
His concerns weren't just about his own balance sheet. "Did our executive branch just set fire to my hopes and expectation to be able to enjoy the 40+ years of hard work?" he asked.
He's not alone. Many older Americans—especially late savers or small business owners—<a href="https://www.benzinga.com/personal-finance/24/11/41918104/are-you-on-track-to-retire-rich-heres-the-nest-egg-you-need-to-be-considered-a-wealthy-retiree">are looking at their retirement plans</a> and wondering if the ground is shifting beneath them. Even those with some savings are finding that higher costs, uncertain markets, and geopolitical tension are chipping away at long-held expectations.
"I'm glad I'm not young and I feel really bad for my adult children going through these times," one commenter wrote, saying they're now prioritizing <a href="https://www.benzinga.com/personal-finance/24/11/41987495/the-greatest-wealth-transfer-in-history-is-here-but-72-of-americans-say-theyre-not-ready-for-it">leaving money behind for their kids</a> instead of spending it themselves.
Trending: ‘Scrolling To UBI' — Deloitte's #1 fastest-growing software company allows users to earn money on their phones. <a href="https://www.benzinga.com/money/mode-mobile-2">You can invest today for just $0.26/share with a $1000 minimum.</a>
Others pushed back on the gloom, pointing to market resilience: "Where was the market a year ago? Look at the last five years—things have gone on a major tear." A market dip, one said, might actually be a good opportunity for younger investors to jump in.
But one reply hit on something deeper: "The market recovering doesn't fix the damage being done, which is structural." From global trust in the U.S. dollar to growing geopolitical friction, the poster argued that the economic model itself may be shifting in ways that don't resemble anything retirees saw in 2008—or ever.
For this 65-year-old business owner, retirement isn't about a 401(k) or a cushy pension. It's about figuring out how to wind down a niche business with no clear resale value, relocate from expensive New York, and support a partner who hasn't been able to save.
See Also: BlackRock is calling 2025 the year of alternative assets. <a href="https://www.benzinga.com/money/masterworks">One firm from NYC has quietly built a group of 60,000+ investors who have all joined in on an alt asset class previously exclusive to billionaires like Bezos and Gates.</a>
He's cobbled together "some $" that could sustain them both, but he's not sure it's enough. And that uncertainty—about both personal finances and the bigger picture—is what seems to be hitting a nerve.
For millions of <a href="https://www.benzinga.com/personal-finance/25/04/44639000/thats-a-lot-billionaire-blackrock-ceo-larry-fink-says-people-need-2-08-million-to-retire-comfortably-but-almost-no-one-is-close">Americans approaching retirement age</a>, the question isn't just whether the market will bounce back. It's whether the next 20 years will look anything like the last 40—and if all that effort will buy the retirement they've been promised for decades.
Read Next:
<ul>
<li>Can you guess how many retire with a $5,000,000 nest egg? <a href="https://www.benzinga.com/money/5mil-nest-egg-adv">The percentage may shock you</a>.</li>
<li>Deloitte's fastest-growing software company partners with Amazon, Walmart &amp; Target – <a href="https://www.benzinga.com/money/mode-mobile-2">Many are rushing to grab 4,000 of its pre-IPO shares for just $0.26/share!</a></li>
</ul>

'Is This the Worst Time to Be 65 in America?' — Business Owner Fears 'Executive Branch' Crushed His Retirement Dreams After 40 + Years Of Hard Work

In the preceding three months, 8 analysts have released ratings for CVS Health (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CVS#NYSE">CVS</a>), presenting a wide array of perspectives from bullish to bearish.
The following table summarizes their recent ratings, shedding light on the changing sentiments within the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">7</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated CVS Health and provided 12-month price targets. The average target is $74.12, accompanied by a high estimate of $81.00 and a low estimate of $65.00. This current average has increased by 10.63% from the previous average price target of $67.00. 
<img src="https://www.benzinga.com/files/images/story/2025/1744236061_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
The analysis of recent analyst actions sheds light on the perception of CVS Health by financial experts. The following summary presents key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Ann Hynes &#x7C;Mizuho &#x7C;Raises &#x7C;Outperform &#x7C; $76.00&#x7C;$70.00 &#x7C; 
&#x7C;Jessica Tassan &#x7C;Piper Sandler &#x7C;Raises &#x7C;Overweight &#x7C; $74.00&#x7C;$72.00 &#x7C; 
&#x7C;Lisa Gill &#x7C;JP Morgan &#x7C;Raises &#x7C;Overweight &#x7C; $81.00&#x7C;$80.00 &#x7C; 
&#x7C;Stephen Baxter &#x7C;Wells Fargo &#x7C;Raises &#x7C;Overweight &#x7C; $73.00&#x7C;$68.00 &#x7C; 
&#x7C;David Macdonald &#x7C;Truist Securities &#x7C;Raises &#x7C;Buy &#x7C; $76.00&#x7C;$60.00 &#x7C; 
&#x7C;Andrew Mok &#x7C;Barclays &#x7C;Raises &#x7C;Overweight &#x7C; $73.00&#x7C;$71.00 &#x7C; 
&#x7C;Michael Cherny &#x7C;Leerink Partners &#x7C;Raises &#x7C;Outperform &#x7C; $75.00&#x7C;$55.00 &#x7C; 
&#x7C;Elizabeth Anderson &#x7C;Evercore ISI Group &#x7C;Raises &#x7C;Outperform &#x7C; $65.00&#x7C;$60.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to CVS Health. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts unravel qualitative evaluations for stocks, ranging from 'Outperform' to 'Underperform'. These ratings offer insights into expectations for the relative performance of CVS Health compared to the broader market.</li>
<li>Price Targets: Delving into movements, analysts provide estimates for the future value of CVS Health's stock. This analysis reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of CVS Health's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/CVS/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on CVS Health analyst ratings.</a>
<h2>Delving into CVS Health's Background</h2>
CVS Health offers a diverse set of healthcare services. Its roots are in its retail pharmacy operations, where it operates over 9,000 stores primarily in the US. CVS is also a large pharmacy benefit manager (acquired through Caremark), processing about 2 billion adjusted claims annually. It also operates a top-tier health insurer (acquired through Aetna) where it serves about 27 million medical members. The company's recent acquisition of Oak Street adds primary care services to the mix, which could have significant synergies with all existing business lines.
<h3>A Deep Dive into CVS Health's Financials</h3>
Market Capitalization: Surpassing industry standards, the company's market capitalization asserts its dominance in terms of size, suggesting a robust market position.
Revenue Growth: Over the 3M period, CVS Health showcased positive performance, achieving a revenue growth rate of 4.15% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Health Care sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 1.68%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): CVS Health's ROE is below industry standards, pointing towards difficulties in efficiently utilizing equity capital. With an ROE of 2.18%, the company may encounter challenges in delivering satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.65%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: CVS Health's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 1.1.
<h2>The Basics of Analyst Ratings</h2>
Experts in banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their comprehensive research involves attending company conference calls and meetings, analyzing financial statements, and engaging with insiders to generate what are known as analyst ratings for stocks. Typically, analysts assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Analyst Ratings

What 8 Analyst Ratings Have To Say About CVS Health

Providing a diverse range of perspectives from bullish to bearish, 9 analysts have published ratings on Ford Motor (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/F#NYSE">F</a>) in the last three months.
Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">4</td>
<td align="right">2</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Providing deeper insights, analysts have established 12-month price targets, indicating an average target of $10.39, along with a high estimate of $15.50 and a low estimate of $7.00. This current average has decreased by 16.07% from the previous average price target of $12.38. 
<img src="https://www.benzinga.com/files/images/story/2025/1744236054_0.png" alt="price target chart" />
<h2>Investigating Analyst Ratings: An Elaborate Study</h2>
In examining recent analyst actions, we gain insights into how financial experts perceive Ford Motor. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Daniel Roeska &#x7C;Bernstein &#x7C;Lowers &#x7C;Underperform &#x7C; $7.00&#x7C;$9.40 &#x7C; 
&#x7C;Ryan Brinkman &#x7C;JP Morgan &#x7C;Lowers &#x7C;Overweight &#x7C; $11.00&#x7C;$13.00 &#x7C; 
&#x7C;Alexander Potter &#x7C;Piper Sandler &#x7C;Lowers &#x7C;Neutral &#x7C; $9.00&#x7C;$13.00 &#x7C; 
&#x7C;Chris McNally &#x7C;Evercore ISI Group &#x7C;Lowers &#x7C;In-Line &#x7C; $10.00&#x7C;$11.00 &#x7C; 
&#x7C;Ryan Brinkman &#x7C;JP Morgan &#x7C;Lowers &#x7C;Overweight &#x7C; $13.00&#x7C;$14.00 &#x7C; 
&#x7C;Tom Narayan &#x7C;RBC Capital &#x7C;Lowers &#x7C;Sector Perform &#x7C; $9.00&#x7C;$10.00 &#x7C; 
&#x7C;Colin Langan &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Underweight &#x7C; $8.00&#x7C;$9.00 &#x7C; 
&#x7C;John Murphy &#x7C;B of A Securities &#x7C;Lowers &#x7C;Buy &#x7C; $15.50&#x7C;$19.00 &#x7C; 
&#x7C;Dan Levy &#x7C;Barclays &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $11.00&#x7C;$13.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Responding to changing market dynamics and company performance, analysts update their recommendations. Whether they 'Maintain', 'Raise', or 'Lower' their stance, it signifies their response to recent developments related to Ford Motor. This offers insight into analysts' perspectives on the current state of the company.</li>
<li>Rating: Gaining insights, analysts provide qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Ford Motor compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Ford Motor's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
For valuable insights into Ford Motor's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/F/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Ford Motor analyst ratings.</a>
<h2>Delving into Ford Motor's Background</h2>
Ford Motor Co. manufactures automobiles under its Ford and Lincoln brands. In March 2022, the company announced that it will run its combustion engine business, Ford Blue, and its BEV business, Ford Model e, as separate businesses but still all under Ford Motor. The company has nearly 13% market share in the United States, about 10% share in the UK, and under 2% share in China including unconsolidated affiliates. Sales in the US made up about 68% of 2024 total company revenue. Ford has about 171,000 employees, including about 56,500 UAW employees, and is based in Dearborn, Michigan.
<h3>Breaking Down Ford Motor's Financial Performance</h3>
Market Capitalization Perspectives: The company's market capitalization falls below industry averages, signaling a relatively smaller size compared to peers. This positioning may be influenced by factors such as perceived growth potential or operational scale.
Revenue Growth: Ford Motor displayed positive results in 3M. As of 31 December, 2024, the company achieved a solid revenue growth rate of approximately 4.89%. This indicates a notable increase in the company's top-line earnings. In comparison to its industry peers, the company trails behind with a growth rate lower than the average among peers in the Consumer Discretionary sector.
Net Margin: Ford Motor's net margin is impressive, surpassing industry averages. With a net margin of 3.78%, the company demonstrates strong profitability and effective cost management.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 4.09%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): Ford Motor's financial strength is reflected in its exceptional ROA, which exceeds industry averages. With a remarkable ROA of 0.64%, the company showcases efficient use of assets and strong financial health.
Debt Management: Ford Motor's debt-to-equity ratio is notably higher than the industry average. With a ratio of 3.59, the company relies more heavily on borrowed funds, indicating a higher level of financial risk.
<h2>The Significance of Analyst Ratings Explained</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
In addition to their assessments, some analysts extend their insights by offering predictions for key metrics such as earnings, revenue, and growth estimates. This supplementary information provides further guidance for traders. It is crucial to recognize that, despite their specialization, analysts are human and can only provide forecasts based on their beliefs.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Beyond The Numbers: 9 Analysts Discuss Ford Motor Stock

In the preceding three months, 12 analysts have released ratings for Shake Shack (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHAK#NYSE">SHAK</a>), presenting a wide array of perspectives from bullish to bearish.
In the table below, you'll find a summary of their recent ratings, revealing the shifting sentiments over the past 30 days and comparing them to the previous months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">4</td>
<td align="right">1</td>
<td align="right">6</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">2</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Shake Shack and provided 12-month price targets. The average target is $122.25, accompanied by a high estimate of $154.00 and a low estimate of $85.00. A decline of 4.49% from the prior average price target is evident in the current average. 
<img src="https://www.benzinga.com/files/images/story/2025/1744236046_0.png" alt="price target chart" />
<h2>Analyzing Analyst Ratings: A Detailed Breakdown</h2>
The standing of Shake Shack among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Brian Bittner &#x7C;Oppenheimer &#x7C;Lowers &#x7C;Outperform &#x7C; $125.00&#x7C;$155.00 &#x7C; 
&#x7C;David Tarantino &#x7C;Baird &#x7C;Lowers &#x7C;Neutral &#x7C; $85.00&#x7C;$98.00 &#x7C; 
&#x7C;Alton Stump &#x7C;Loop Capital &#x7C;Announces &#x7C;Buy &#x7C; $127.00&#x7C;- &#x7C; 
&#x7C;Anthony Trainor &#x7C;Wells Fargo &#x7C;Announces &#x7C;Equal-Weight &#x7C; $95.00&#x7C;- &#x7C; 
&#x7C;John Ivankoe &#x7C;JP Morgan &#x7C;Lowers &#x7C;Underweight &#x7C; $105.00&#x7C;$107.00 &#x7C; 
&#x7C;Jake Bartlett &#x7C;Truist Securities &#x7C;Raises &#x7C;Buy &#x7C; $154.00&#x7C;$143.00 &#x7C; 
&#x7C;Nick Setyan &#x7C;Wedbush &#x7C;Raises &#x7C;Neutral &#x7C; $125.00&#x7C;$115.00 &#x7C; 
&#x7C;Andrew Charles &#x7C;TD Securities &#x7C;Maintains &#x7C;Buy &#x7C; $140.00&#x7C;$140.00 &#x7C; 
&#x7C;Chris O'Cull &#x7C;Stifel &#x7C;Lowers &#x7C;Hold &#x7C; $110.00&#x7C;$128.00 &#x7C; 
&#x7C;Nick Setyan &#x7C;Wedbush &#x7C;Maintains &#x7C;Neutral &#x7C; $130.00&#x7C;$130.00 &#x7C; 
&#x7C;Jake Bartlett &#x7C;Truist Securities &#x7C;Lowers &#x7C;Buy &#x7C; $143.00&#x7C;$149.00 &#x7C; 
&#x7C;Chris O'Cull &#x7C;Stifel &#x7C;Raises &#x7C;Hold &#x7C; $128.00&#x7C;$115.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Shake Shack. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analysts assign qualitative assessments to stocks, ranging from 'Outperform' to 'Underperform'. These ratings convey the analysts' expectations for the relative performance of Shake Shack compared to the broader market.</li>
<li>Price Targets: Analysts gauge the dynamics of price targets, providing estimates for the future value of Shake Shack's stock. This comparison reveals trends in analysts' expectations over time.</li>
</ul>
Understanding these analyst evaluations alongside key financial indicators can offer valuable insights into Shake Shack's market standing. Stay informed and make well-considered decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/SHAK/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Shake Shack analyst ratings.</a>
<h2>Discovering Shake Shack: A Closer Look</h2>
Shake Shack Inc is a roadside burger stand. It serves a classic American menu of premium burgers, hot dogs, crispy chicken, frozen custard, crinkle-cut fries, shakes, beer, wine and more. The company's burgers are made with a whole-muscle blend of all-natural, hormone and antibiotic-free Angus beef, ground fresh daily, cooked to order, and served on a non-genetically modified organism (GMO) potato bun. Its menu focuses on food and beverages, crafted from a range of classic American foods. The company serves draft Root Beer, seasonal freshly-squeezed lemonade, organic fresh brewed iced tea, cold brew coffee, organic apple juice, and Shack20 bottled water.
<h3>Financial Insights: Shake Shack</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Over the 3M period, Shake Shack showcased positive performance, achieving a revenue growth rate of 14.83% as of 31 December, 2024. This reflects a substantial increase in the company's top-line earnings. In comparison to its industry peers, the company stands out with a growth rate higher than the average among peers in the Consumer Discretionary sector.
Net Margin: Shake Shack's net margin lags behind industry averages, suggesting challenges in maintaining strong profitability. With a net margin of 2.65%, the company may face hurdles in effective cost management.
Return on Equity (ROE): The company's ROE is below industry benchmarks, signaling potential difficulties in efficiently using equity capital. With an ROE of 1.88%, the company may need to address challenges in generating satisfactory returns for shareholders.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.52%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Shake Shack's debt-to-equity ratio is below the industry average at 1.72, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>Analyst Ratings: Simplified</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts also offer predictions for helpful metrics such as earnings, revenue, and growth estimates to provide further guidance as to what to do with certain tickers. It is important to keep in mind that while stock and sector analysts are specialists, they are also human and can only forecast their beliefs to traders.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

SHAK

Expert Outlook: Shake Shack Through The Eyes Of 12 Analysts

Ratings for Park Hotels &amp; Resorts (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PK#NYSE">PK</a>) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The following table provides a quick overview of their recent ratings, highlighting the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
Analysts have recently evaluated Park Hotels &amp; Resorts and provided 12-month price targets. The average target is $13.25, accompanied by a high estimate of $16.00 and a low estimate of $10.00. A negative shift in sentiment is evident as analysts have decreased the average price target by 23.19%. 
<img src="https://www.benzinga.com/files/images/story/2025/1744236034_0.png" alt="price target chart" />
<h2>Decoding Analyst Ratings: A Detailed Look</h2>
A clear picture of Park Hotels &amp; Resorts's perception among financial experts is painted with a thorough analysis of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;David Katz &#x7C;Jefferies &#x7C;Lowers &#x7C;Hold &#x7C; $10.00&#x7C;$19.00 &#x7C; 
&#x7C;Patrick Scholes &#x7C;Truist Securities &#x7C;Lowers &#x7C;Buy &#x7C; $16.00&#x7C;$18.00 &#x7C; 
&#x7C;Dori Kesten &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $14.00&#x7C;$17.00 &#x7C; 
&#x7C;Robin Farley &#x7C;UBS &#x7C;Lowers &#x7C;Neutral &#x7C; $13.00&#x7C;$15.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts respond to changes in market conditions and company performance, frequently updating their recommendations. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Park Hotels &amp; Resorts. This information offers a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Park Hotels &amp; Resorts compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Park Hotels &amp; Resorts's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Capture valuable insights into Park Hotels &amp; Resorts's market standing by understanding these analyst evaluations alongside pertinent financial indicators. Stay informed and make strategic decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PK/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Park Hotels &amp; Resorts analyst ratings.</a>
<h2>About Park Hotels &amp; Resorts</h2>
Park Hotels &amp; Resorts owns upper-upscale and luxury hotels with 22,711 rooms across 37 hotels in the United States. Park also has interests through joint ventures in another 2,271 rooms in three US hotels. Park was spun out of narrow-moat Hilton Worldwide Holdings at the start of 2017, so most of the company's hotels are still under Hilton brands. The company has sold all its international hotels and many of its lower-quality US hotels to focus on high-quality assets in domestic gateway markets.
<h3>Park Hotels &amp; Resorts: Financial Performance Dissected</h3>
Market Capitalization Analysis: With a profound presence, the company's market capitalization is above industry averages. This reflects substantial size and strong market recognition.
Revenue Growth: Park Hotels &amp; Resorts's revenue growth over a period of 3M has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately -4.87%. This indicates a decrease in the company's top-line earnings. When compared to others in the Real Estate sector, the company faces challenges, achieving a growth rate lower than the average among peers.
Net Margin: Park Hotels &amp; Resorts's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 10.4% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Park Hotels &amp; Resorts's ROE stands out, surpassing industry averages. With an impressive ROE of 1.76%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Park Hotels &amp; Resorts's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.71% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: The company maintains a balanced debt approach with a debt-to-equity ratio below industry norms, standing at 1.31.
<h2>The Significance of Analyst Ratings Explained</h2>
Analysts are specialists within banking and financial systems that typically report for specific stocks or within defined sectors. These people research company financial statements, sit in conference calls and meetings, and speak with relevant insiders to determine what are known as analyst ratings for stocks. Typically, analysts will rate each stock once a quarter. 
Some analysts publish their predictions for metrics such as growth estimates, earnings, and revenue to provide additional guidance with their ratings. When using analyst ratings, it is important to keep in mind that stock and sector analysts are also human and are only offering their opinions to investors.
If you want to keep track of which analysts are outperforming others, you can view updated analyst ratings along withanalyst success scores in <a href="https://www.benzinga.com/pro/">Benzinga Pro</a>.
Breaking: Wall Street's Next Big Mover
Benzinga's #1 analyst just identified a stock poised for explosive growth. This under-the-radar company could surge 200%+ as major market shifts unfold. <a href="https://www.benzinga.com/premium/ideas/turning-point-trader-checkout-2/?t=Tu1tu3arja3be22tu36&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantag">Click here for urgent details</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

4 Analysts Assess Park Hotels & Resorts: What You Need To Know

Across the recent three months, 6 analysts have shared their insights on Pinnacle Finl Partners (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/PNFP#NASDAQ">PNFP</a>), expressing a variety of opinions spanning from bullish to bearish.
The table below provides a concise overview of recent ratings by analysts, offering insights into the changing sentiments over the past 30 days and drawing comparisons with the preceding months for a holistic perspective.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">2</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $126.5, a high estimate of $142.00, and a low estimate of $105.00. Observing a downward trend, the current average is 5.01% lower than the prior average price target of $133.17. 
<img src="https://www.benzinga.com/files/images/story/2025/1744236026_0.png" alt="price target chart" />
<h2>Deciphering Analyst Ratings: An In-Depth Analysis</h2>
The standing of Pinnacle Finl Partners among financial experts is revealed through an in-depth exploration of recent analyst actions. The summary below outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;--------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Timur Braziler &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $105.00&#x7C;$125.00 &#x7C; 
&#x7C;Jared Shaw &#x7C;Barclays &#x7C;Lowers &#x7C;Overweight &#x7C; $125.00&#x7C;$135.00 &#x7C; 
&#x7C;Brett Rabatin &#x7C;Hovde Group &#x7C;Lowers &#x7C;Market Perform &#x7C; $120.00&#x7C;$135.00 &#x7C; 
&#x7C;Russell Gunther &#x7C;Stephens &amp; Co. &#x7C;Maintains &#x7C;Overweight &#x7C; $142.00&#x7C;$142.00 &#x7C; 
&#x7C;Steven Shaw &#x7C;Wells Fargo &#x7C;Raises &#x7C;Equal-Weight &#x7C; $125.00&#x7C;$120.00 &#x7C; 
&#x7C;Russell Gunther &#x7C;Stephens &amp; Co. &#x7C;Maintains &#x7C;Overweight &#x7C; $142.00&#x7C;$142.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Pinnacle Finl Partners. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Providing a comprehensive analysis, analysts offer qualitative assessments, ranging from 'Outperform' to 'Underperform'. These ratings reflect expectations for the relative performance of Pinnacle Finl Partners compared to the broader market.</li>
<li>Price Targets: Understanding forecasts, analysts offer estimates for Pinnacle Finl Partners's future value. Examining the current and prior targets provides insight into analysts' changing expectations.</li>
</ul>
Considering these analyst evaluations in conjunction with other financial indicators can offer a comprehensive understanding of Pinnacle Finl Partners's market position. Stay informed and make well-informed decisions with our Ratings Table.
<a href="https://www.benzinga.com/quote/PNFP/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Pinnacle Finl Partners analyst ratings.</a>
<h2>Delving into Pinnacle Finl Partners's Background</h2>
Pinnacle Financial Partners Inc is a financial holding company. The company operates through its wholly-owned subsidiary, Pinnacle Bank. The bank provides a full range of lending products, including commercial, real estate, and consumer loans to individuals and small to medium-sized businesses. It operates as a community bank mainly in the urban markets of Nashville, Knoxville, Memphis, and Chattanooga, Tennessee, as well as surrounding counties. It relies heavily on mergers and acquisitions. A majority of its loan portfolio is in commercial loans, mainly real estate, as well as industrial loans. The bank generates a majority of its net revenue through net interest income.
<h3>Key Indicators: Pinnacle Finl Partners's Financial Health</h3>
Market Capitalization Analysis: Reflecting a smaller scale, the company's market capitalization is positioned below industry averages. This could be attributed to factors such as growth expectations or operational capacity.
Revenue Growth: Pinnacle Finl Partners's revenue growth over a period of 3M has been noteworthy. As of 31 December, 2024, the company achieved a revenue growth rate of approximately 30.22%. This indicates a substantial increase in the company's top-line earnings. As compared to its peers, the revenue growth lags behind its industry peers. The company achieved a growth rate lower than the average among peers in Financials sector.
Net Margin: The company's net margin is a standout performer, exceeding industry averages. With an impressive net margin of 34.7%, the company showcases strong profitability and effective cost control.
Return on Equity (ROE): Pinnacle Finl Partners's ROE falls below industry averages, indicating challenges in efficiently using equity capital. With an ROE of 2.39%, the company may face hurdles in generating optimal returns for shareholders.
Return on Assets (ROA): Pinnacle Finl Partners's ROA is below industry standards, pointing towards difficulties in efficiently utilizing assets. With an ROA of 0.29%, the company may encounter challenges in delivering satisfactory returns from its assets.
Debt Management: Pinnacle Finl Partners's debt-to-equity ratio is below industry norms, indicating a sound financial structure with a ratio of 0.37.
<h2>The Basics of Analyst Ratings</h2>
Within the domain of banking and financial systems, analysts specialize in reporting for specific stocks or defined sectors. Their work involves attending company conference calls and meetings, researching company financial statements, and communicating with insiders to publish "analyst ratings" for stocks. Analysts typically assess and rate each stock once per quarter.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

PNFP

A Glimpse Into The Expert Outlook On Pinnacle Finl Partners Through 6 Analysts

In the current session, the stock is trading at $128.09, after a 11.75% spike. Over the past month, Howmet Aerospace Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HWM#NYSE">HWM</a>) stock increased by 0.13%, and in the past year, by 95.29%. With performance like this, long-term shareholders are optimistic but others are more likely to look into the price-to-earnings ratio to see if the stock might be overvalued.

<img src="https://www.benzinga.com/files/images/story/2025/1744236018_0.png" alt="Past Year Chart" />

<h3>How Does Howmet Aerospace P/E Compare to Other Companies?</h3>
The P/E ratio measures the current share price to the company's EPS. It is used by long-term investors to analyze the company's current performance against it's past earnings, historical data and aggregate market data for the industry or the indices, such as S&amp;P 500. A higher P/E indicates that investors expect the company to perform better in the future, and the stock is probably overvalued, but not necessarily. It also could indicate that investors are willing to pay a higher share price currently, because they expect the company to perform better in the upcoming quarters. This leads investors to also remain optimistic about rising dividends in the future. 
Compared to the aggregate P/E ratio of the 120.66 in the Aerospace &amp; Defense industry, Howmet Aerospace Inc. has a lower P/E ratio of 40.79. Shareholders might be inclined to think that the stock might perform worse than it's industry peers. It's also possible that the stock is undervalued. 

<img src="https://www.benzinga.com/files/images/story/2025/1744236018_1.png" alt="Guage" />

In summary, while the price-to-earnings ratio is a valuable tool for investors to evaluate a company's market performance, it should be used with caution. A low P/E ratio can be an indication of undervaluation, but it can also suggest weak growth prospects or financial instability. Moreover, the P/E ratio is just one of many metrics that investors should consider when making investment decisions, and it should be evaluated alongside other financial ratios, industry trends, and qualitative factors. By taking a comprehensive approach to analyzing a company's financial health, investors can make well-informed decisions that are more likely to lead to successful outcomes.

Intraday Update

A Look Into Howmet Aerospace Inc's Price Over Earnings

Ratings for Columbia Banking System (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/COLB#NASDAQ">COLB</a>) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.
The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th align="right">Bullish</th>
<th align="right">Somewhat Bullish</th>
<th align="right">Indifferent</th>
<th align="right">Somewhat Bearish</th>
<th align="right">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">4</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">1</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td align="right">0</td>
<td align="right">0</td>
<td align="right">3</td>
<td align="right">0</td>
<td align="right">0</td>
</tr>
</tbody>
</table>
The 12-month price targets assessed by analysts reveal further insights, featuring an average target of $29.4, a high estimate of $33.00, and a low estimate of $26.00. Observing a downward trend, the current average is 11.45% lower than the prior average price target of $33.20. 
<img src="https://www.benzinga.com/files/images/story/2025/1744236015_0.png" alt="price target chart" />
<h2>Diving into Analyst Ratings: An In-Depth Exploration</h2>
A comprehensive examination of how financial experts perceive Columbia Banking System is derived from recent analyst actions. The following is a detailed summary of key analysts, their recent evaluations, and adjustments to ratings and price targets.
&#x7C; Analyst &#x7C; Analyst Firm &#x7C; Action Taken &#x7C; Rating &#x7C;Current Price Target&#x7C; Prior Price Target &#x7C; 
&#x7C;--------------------&#x7C;-----------------------&#x7C;---------------&#x7C;---------------&#x7C;--------------------&#x7C;--------------------&#x7C; 
&#x7C;Jared Shaw &#x7C;Wells Fargo &#x7C;Lowers &#x7C;Overweight &#x7C; $26.00&#x7C;$35.00 &#x7C; 
&#x7C;Jared Shaw &#x7C;Barclays &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $27.00&#x7C;$33.00 &#x7C; 
&#x7C;Andrew Terrell &#x7C;Stephens &amp; Co. &#x7C;Lowers &#x7C;Equal-Weight &#x7C; $31.00&#x7C;$33.00 &#x7C; 
&#x7C;Ben Gerlinger &#x7C;Citigroup &#x7C;Lowers &#x7C;Neutral &#x7C; $30.00&#x7C;$31.00 &#x7C; 
&#x7C;Christopher Mcgratty&#x7C;Keefe, Bruyette &amp; Woods&#x7C;Lowers &#x7C;Market Perform &#x7C; $33.00&#x7C;$34.00 &#x7C;
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts frequently update their recommendations based on evolving market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their reaction to recent developments related to Columbia Banking System. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Analyzing trends, analysts offer qualitative evaluations, ranging from 'Outperform' to 'Underperform'. These ratings convey expectations for the relative performance of Columbia Banking System compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Columbia Banking System's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
Assessing these analyst evaluations alongside crucial financial indicators can provide a comprehensive overview of Columbia Banking System's market position. Stay informed and make well-judged decisions with the assistance of our Ratings Table.
<a href="https://www.benzinga.com/quote/COLB/analyst-ratings?adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Stay up to date on Columbia Banking System analyst ratings.</a>
<h2>About Columbia Banking System</h2>
Columbia Banking System Inc is a registered bank holding company whose wholly-owned banking subsidiary is Columbia State Bank. The company provides a full range of banking services to small and medium sized businesses, professionals, and individuals throughout Washington, Oregon, Idaho, and California. The company's subsidiary Columbia Trust Company is an Oregon trust company that provides agency, fiduciary, and other related trust services with offices in Washington, Oregon, and Idaho. The firm offers various products and services under Personal Banking, Business Banking, and Wealth Management divisions.
<h3>Columbia Banking System: Delving into Financials</h3>
Market Capitalization Analysis: The company's market capitalization is below the industry average, suggesting that it is relatively smaller compared to peers. This could be due to various factors, including perceived growth potential or operational scale.
Revenue Growth: Columbia Banking System's revenue growth over a period of 3M has faced challenges. As of 31 December, 2024, the company experienced a revenue decline of approximately -6.17%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Financials sector.
Net Margin: Columbia Banking System's net margin excels beyond industry benchmarks, reaching 29.41%. This signifies efficient cost management and strong financial health.
Return on Equity (ROE): The company's ROE is a standout performer, exceeding industry averages. With an impressive ROE of 2.76%, the company showcases effective utilization of equity capital.
Return on Assets (ROA): The company's ROA is below industry benchmarks, signaling potential difficulties in efficiently utilizing assets. With an ROA of 0.28%, the company may need to address challenges in generating satisfactory returns from its assets.
Debt Management: Columbia Banking System's debt-to-equity ratio surpasses industry norms, standing at 0.72. This suggests the company carries a substantial amount of debt, posing potential financial challenges.
<h2>The Core of Analyst Ratings: What Every Investor Should Know</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may supplement their ratings with predictions for metrics like growth estimates, earnings, and revenue, offering investors a more comprehensive outlook. However, investors should be mindful that analysts, like any human, can have subjective perspectives influencing their forecasts.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;adType=benzinga-insights&amp;ad=analyst-ratings&amp;campaign=wallstreetadvantage">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

COLB

Beyond The Numbers: 5 Analysts Discuss Columbia Banking System Stock

General

Enact Holdings To Replace SolarWinds Corp. In The S&P SmallCap 600, Effective April 16,2025

United States Steel Corp (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/X#NYSE">X</a>) shares are getting crushed in Wednesday&#8217;s after-hours session after President Donald Trump suggested he doesn&#8217;t want to see the company get <a href="https://www.benzinga.com/markets/commodities/25/04/44679320/us-steel-gains-16-as-trump-orders-review-of-nippon-steels-blocked-acquisition-amid-national-security-concerns">acquired by Nippon Steel</a>.
What Happened: In a <a href="https://www.youtube.com/watch?v=qr9AeMFXzpY">press conference</a> from the Oval Office late Wednesday, Trump said he wants U.S. Steel to remain a U.S. company. 
&#8220;We don&#8217;t want to see it go to Japan. You know, we love Japan, but U.S. Steel is a very special company,&#8221; Trump said. 
The news comes just a day after U.S. Steel shares surged after Trump ordered a <a href="https://www.benzinga.com/markets/commodities/25/04/44679320/us-steel-gains-16-as-trump-orders-review-of-nippon-steels-blocked-acquisition-amid-national-security-concerns">national security review</a> of the company&#8217;s takeover deal with Nippon Steel, which was blocked by the Biden Administration. 
U.S. Steel and Nippon Steel filed lawsuits in January in response to what the companies said was &#8220;wrongful interference&#8221; with Nippon's proposed $14.9-billion acquisition of U.S. Steel, originally announced at the end of 2023.
The Biden administration said last year that&nbsp;<a href="https://www.benzinga.com/news/24/07/39613777/amid-opposition-from-biden-and-workers-nippon-steel-vc-returns-to-discuss-us-steel-acquisition" target="_blank" rel="noreferrer noopener">it was &#8220;vital&#8221;</a>&nbsp;that U.S. Steel remained a domestically operated American steel company. The proposed acquisition had become a major topic of discussion leading up to the&nbsp;presidential election in November.
X Price Action: <a href="http://benzinga.com/quote/X">U.S. Steel shares</a> were down 11.39% after-hours, trading at $39.98 at the time of publication Wednesday, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/04/44723376/goldman-sachs-scraps-recession-call-after-trumps-surprise-tariff-pause-as-wall-street-marks-strongest-day-since-2008">Goldman Sachs Scraps Recession Call After Trump&#8217;s Surprise Tariff Pause As Wall Street Marks Strongest Day Since 2008</a></li>
</ul>
Photo: Shutterstock.

Commodities

Global

After-Hours Center

US Steel Stock Tumbles As Trump Says 'We Don't Want To See It Go To Japan'

KKR &amp; Co. Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/KKR#NYSE">KKR</a>) has secured a deal to acquire Swedish consumer health firm Karo Healthcare<a target="_blank" href="https://www.benzinga.com/25/02/43907861/kkr-to-gain-full-control-of-hcg-in-400-million-deal-eyes-healthcare-expansion" rel="noreferrer noopener">.</a>
The transaction is subject to customary regulatory conditions and approvals and is expected to close in the coming months, per a <a target="_blank" href="https://eqtgroup.com/news/eqt-to-sell-karo-healthcare-a-leading-pan-european-consumer-health-platform-to-kkr-2025-04-09" rel="noreferrer noopener">statement</a>.&nbsp;
"We engaged the full capabilities of our firm to deliver this transaction during a period of market disruption and we look forward to supporting Karo's growth as a value-enhancing strategic partner," said Hans Arstad, Managing Director at KKR.
The transaction, expected to be valued at approximately 2.65 billion euros ($2.924 billion) including debt, would see KKR beat out rival bidder PAI Partners to secure the company behind popular over-the-counter brands like E45 and Lamisil, Financial Times <a target="_blank" href="https://www.ft.com/content/59680d34-adb9-473a-8c95-9f89ac9e1555" rel="noreferrer noopener">reports</a>.
Also Read: <a target="_blank" href="https://www.benzinga.com/general/health-care/25/03/44514266/kkr-mulls-to-buy-japan-based-eye-care-company-topcon" rel="noreferrer noopener">KKR Mulls To Buy Japan-Based Eye Care Company Topcon</a>
Karo Healthcare, headquartered in Stockholm, has expanded significantly under the ownership of EQT, which took the firm private in 2022 at a valuation of 1.4 billion euros.
EQT initially took a majority stake in Karo back in 2019 when the business was still listed, Financial Times adds.
The acquisition underscores KKR's confidence in healthcare-focused investments even as overall merger activity has slowed due to uncertain interest rate policy and fluctuating debt markets.
The buyout is poised to provide a strong return for EQT, following a series of brand acquisitions Karo made in recent years.
Under EQT's stewardship, Karo spent £200 million in 2021 to acquire the E45 skincare line from Reckitt Benckiser Group Plc (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RBGLY#OTC">RBGLY</a>), and in 2023 it purchased Lamisil from Haleon Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HLN#NYSE">HLN</a>) for £235 million. The company currently markets over 100 products across 90 countries, with a portfolio that includes Nutravita, Alpha Foods, and Remescar. Karo employs about 400 people globally.
This deal would further KKR's extensive footprint in the European healthcare sector.
The firm, which manages $668 billion in assets, has recently invested in U.K.-based Clinisupplies and Swiss peptide manufacturer Biosynth, among others.
According to&nbsp;<a target="_blank" href="https://pro.benzinga.com/?gspk=YWRhbWVja2VydDUzMzY&amp;gsxid=zBMR4PKmcgBw" rel="noreferrer noopener">Benzinga Pro</a>, KKR stock has lost over 5% in the past year. Investors can gain exposure to the stock via FM Focus Equity ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FMCX#NYSE">FMCX</a>).
Price Action: KKR shares closed higher by 16.90% to $110.46&nbsp;on Wednesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/tech/25/04/44706944/elon-musk-warns-those-who-financed-tesla-attacks-will-go-to-prison" target="_blank" rel="noreferrer noopener">Elon Musk Warns Those Who Financed Tesla Attacks ‘Will Go To Prison'</a></li>
</ul>
Photo via Shutterstock

Equities

Media

Northern Lights Fund Trust IV FMC Excelsior Focus Equity ETF

FMCX

RBGLY

KKR Outbids Competitors To Secure $2.9 Billion Karo Healthcare Takeover

Bank shares such as Ameris Bancorp inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ABCB#NYSE">ABCB</a>) and BancFirst Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BANF#NASDAQ">BANF</a>) are trading higher on Wednesday in response to a surprise announcement from President Donald Trump to temporarily pause certain tariffs.
What To Know: The broad-based rally followed Trump's declaration of a 90-day suspension on reciprocal tariffs for countries that have not retaliated against U.S. trade measures. While the pause excludes China — which will now face a 125% tariff on its goods — the shift in policy has eased immediate trade tensions and helped stabilize market sentiment.
A pause in trade escalation reduces uncertainty, which can support business lending, consumer confidence and overall economic activity — all key drivers for banks.
Trump's move was said to be a reward for countries that refrained from retaliating, offering them a temporary 10% tariff and delaying further duties. In contrast, China was singled out as a bad actor, with the president criticizing its trade practices and warning that the U.S. will no longer tolerate the current imbalance.
Treasury Secretary Scott Bessent described the tariff shift as a correction to decades of trade inequities and suggested that the market had previously misunderstood the scope of Trump&#8217;s policy. He called the 10% reciprocal tariff a "temporary floor" that adds clarity and leverage to U.S. trade strategy.
Price Action: Ameris shares closed Wednesday up 8.31% to $54.90 and Bancfirst shares were up 6.08% to $108.29, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2">Benzinga Pro.</a>
Photo: Shutterstock.

ABCB

BANF

Bank Shares Are Up Today: What You Need To Know

U.S.&nbsp;President Donald Trump, on Tuesday, disclosed plans for a "major tariff" on <a target="_blank" href="https://www.benzinga.com/topic/tariffs" rel="noreferrer noopener">foreign pharmaceuticals</a>.
"We're&nbsp;going to be announcing very&nbsp;shortly a major tariff on&nbsp;pharmaceuticals… when they hear that&nbsp;they will leave China, they&nbsp;will leave other places because… most of their product&nbsp;is sold here," Trump expressed at&nbsp;a National Republican <a target="_blank" href="https://www.benzinga.com/25/04/44708204/trump-hints-at-major-tariff-on-imported-pharmaceuticals-us-pharma-stocks-tumble-in-wednesday-pre-market" rel="noreferrer noopener">Congressional Committee&nbsp;dinner</a>.
He also told reporters on board his Air Force One plane that "pharma" tariffs would arrive "at a level that you haven't really seen before," saying these would be announced "in the near future," BBC <a target="_blank" href="https://www.bbc.com/news/articles/cedyylj1v32o" rel="noreferrer noopener">report</a> added.
Also Read: <a target="_blank" href="https://www.benzinga.com/25/04/44698325/trump-tariff-strategy-self-inflicted-market-debacle-says-wedbush-analyst" rel="noreferrer noopener">Trump Tariff Strategy Creates ‘Self-Inflicted Market Debacle': Analyst</a>
When President Trump announced tariffs last week, he excluded pharmaceuticals from the new tariffs, likely a relief for the industry under pressure following his prior comments suggesting a 25% tariff&nbsp;<a target="_blank" href="https://www.benzinga.com/general/biotech/25/04/44652075/us-tariffs-spare-drugmakers-but-threaten-diabetes-device-industry" rel="noreferrer noopener">on pharmaceutical imports</a>.&nbsp;
On Wednesday, in a surprise announcement from President Donald Trump, a 90-day pause on tariffs for countries that have not retaliated <a target="_blank" href="https://www.benzinga.com/topic/tariffs" rel="noreferrer noopener">against U.S. trade measures.</a>
The news ignited a broad risk-on rally, catapulting major indices to multi-month highs and sending volatility plunging.
Trump's latest Truth Social post slammed China for showing "a lack of respect" and declared an immediate 125% tariff hike on Chinese goods.
"At some point, hopefully in the near future, China will realize that the days of ripping off the U.S.A. and other Countries is no longer sustainable or acceptable," he said.
He praised the over 75 countries that, in his words, "have not, at my strong suggestion, retaliated in any way, shape, or form."
As a reward, those countries would benefit from a temporary 10% reciprocal tariff and a 90-day pause on additional duties.
The biopharma industry has historically been shielded from tariffs, including during Trump's first term.
Although Trump didn't provide many details, his remarks have unsettled buyers, especially those who depend on medicines from India. India provides nearly half of all generic drugs used in the U.S., helping cut billions from healthcare costs.
The U.S. is a major market, buying about a third of India's $13 billion in yearly drug exports.
Indian drug companies warn that if tariffs are added, they'd have to raise prices—which could increase healthcare costs in the U.S.
Even though some companies like Cipla and Dr. Reddy's Laboratories Ltd (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/RDY#NYSE">RDY</a>) have factories in the U.S., most say it's too expensive to move production for low-profit generic drugs.
BofA Securities analyst says if the Trump administration plans to impose tariffs on the pharmaceutical industry, it would likely do so through a "Section 232 investigation" under the Trade Expansion Act of 1962 to determine whether importing certain goods threatens national security.
The typical timeline for a Section 232 investigation is about a year. If the same timeline applied here, tariffs on drug imports likely wouldn't take effect until late in the year—at the earliest.
It's unclear whether the Section 232 investigation into the drug industry is about to start, but based on recent comments from the administration, it seems possible. However, launching an investigation doesn't guarantee that tariffs will follow.
As the first quarter 2025 earnings season starts soon, analyst Tim Anderson says it will be worth watching whether companies discuss potential tariffs during earnings calls.
That said, any actual earnings impact likely wouldn't show up until sometime after 2025, which could leave investors with more questions than answers.
Wedbush analyst Daniel Ives <a target="_blank" href="https://www.benzinga.com/25/04/44698325/trump-tariff-strategy-self-inflicted-market-debacle-says-wedbush-analyst" rel="noreferrer noopener">on Tuesday wrote</a> that "saying we can just make this in the USA" understates how complex the supply chain in Asia really is—and how electronics, chips, semiconductors, hardware, and smartphones have been built for U.S. consumers over the past 30 years."
Shares of major drugmakers such as Gilead Sciences&nbsp;Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/GILD#NASDAQ">GILD</a>), Merck&nbsp;&amp; Co Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MRK#NYSE">MRK</a>), Eli Lilly&nbsp;And Co (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LLY#NYSE">LLY</a>), AstraZeneca&nbsp;Plc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AZN#NASDAQ">AZN</a>), Roche&nbsp;Holdings AG (OTC:<a class="ticker" href="https://www.benzinga.com/stock/RHHBY#OTC">RHHBY</a>), Sanofi&nbsp;SA (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/SNY#NASDAQ">SNY</a>), Novartis&nbsp;AG (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVS#NYSE">NVS</a>), Argenx&nbsp;SE (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ARGX#NASDAQ">ARGX</a>), UCB&nbsp;SA (OTC:<a class="ticker" href="https://www.benzinga.com/stock/UCBJY#OTC">UCBJY</a>) (OTC:<a class="ticker" href="https://www.benzinga.com/stock/UCBJF#OTC">UCBJF</a>), Novo Nordisk&nbsp;A/S (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), Regeneron Pharmaceuticals Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/REGN#NASDAQ">REGN</a>) GSK Plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GSK#NYSE">GSK</a>) and Pfizer Inc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>) fell on Wednesday, only reverse course later after the 90-day tariff pause.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/04/44723376/goldman-sachs-scraps-recession-call-after-trumps-surprise-tariff-pause-as-wall-street-marks-strongest-day-since-2008" target="_blank" rel="noreferrer noopener">Goldman Sachs Scraps Recession Call After Trump's Surprise Tariff Pause As Wall Street Marks Strongest Day Since 2008</a></li>
</ul>
Photo by MargJohnsonVA via Shutterstock

Analyst Color

Biotech

Government

Health Care

ARGX

GILD

REGN

RHHBY

UCBJF

UCBJY

Pharma Industry Faces Jitters As Trump Hints At Historic Tariffs, BofA Outlines Probable Timeline

Machinery shares such as Arcosa Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ACA#NYSE">ACA</a>) and Valmont Industries Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/VMI#NYSE">VMI</a>) are trading higher Wednesday on news that President Donald Trump would pause tariffs for<a href="https://www.benzinga.com/25/04/44720006/markets-take-off-as-trump-announces-90-day-tariff-pause-for-non-retaliating-nations-slaps-china-with-125-duty"> most U.S. trading partners. </a>
What To Know: The gains followed a surprise announcement from Trump of a 90-day suspension on reciprocal tariffs for all countries that have not retaliated against previous U.S. trade measures. The move excludes China, which instead will face a sharp increase in tariffs.
Trump&#8217;s decision to reward non-retaliatory nations with a temporary 10% tariff and delay further duties appears to have eased investor fears around escalating trade tensions.
In contrast, Trump sharply criticized China in a Truth Social post, accusing it of exploiting the U.S. and pledging a new 125% tariff on Chinese imports. He stated that over 75 countries had refrained from retaliating and would benefit from the pause.
At a White House press conference, Treasury Secretary Scott Bessent emphasized that the changes reflect an attempt to address long-standing global trade imbalances. He noted that markets previously misunderstood the scale of Trump&#8217;s trade measures and described the 10% reciprocal tariff as a temporary floor that adds clarity going forward.
Bessent also accused Beijing of exacerbating the trade deficit and portraying itself as an uncooperative actor in global trade. He suggested that the new policy would give the U.S. greater leverage to force changes in its trade relationship with China.
Price Action: Arcosa shares closed Wednesday up 10.67% to $78.20 and Valmont Industries shares are up 7.65% to $284.96, according to <a href="https://pro.benzinga.com/dashboard?new_user=False&amp;backend=google-oauth2'">Benzinga Pro.</a> Read Next: • <a href="https://www.benzinga.com/25/04/44720006/markets-take-off-as-trump-announces-90-day-tariff-pause-for-non-retaliating-nations-slaps-china-with-125-duty">Wall Street Roars As Trump Pauses Tariffs For Non-Retaliator, Hikes China Duties To 125%</a>
Photo: Shutterstock.

Machinery Stocks Are Up Today: What's Going On?

Energy Transfer's Subsidiary Energy Transfer LNG Export Enters Into A Heads Of Agreement With MidOcean Energy To Jointly Develop Lake Charles LNG Export Facility.

Trump Media &amp; Technology Group Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/DJT#NASDAQ">DJT</a>) shares soared in afternoon trading Wednesday alongside the broader market after President Donald Trump announced a 90-day pause on reciprocal tariffs. Trump Media shares have carried that momentum into the <a href="https://www.benzinga.com/quote/DJT">after-hours session</a>.
What To Know: Stocks staged a massive rally on Wednesday after Trump announced a 90-day tariff pause in a <a href="https://truthsocial.com/@realDonaldTrump/posts/114309144289505174">post</a> on Truth Social.&nbsp;
&#8220;Based on the fact that more than 75 Countries have called Representatives of the United States &#8230; to negotiate a solution to the subjects being discussed relative to Trade, Trade Barriers, Tariffs, Currency Manipulation, and Non Monetary Tariffs, and that these Countries have not, at my strong suggestion, retaliated in any way, shape, or form against the United States, I have authorized a 90 day PAUSE,&#8221; Trump said in the post. 
The tariff pause will be effective immediately for non-retaliating countries, while China will face a harsh 125% tariff. The announcement came hours after Trump&#8217;s sweeping reciprocal tariffs took effect.
Trump Media, which is the parent company of Truth Social, was&nbsp;<a href="https://www.benzinga.com/25/04/44608924/trump-media-technology-stock-drops-on-share-registration-will-president-trump-sell-his-stake" target="_blank" rel="noreferrer noopener">co-founded by Trump</a>, who maintains more than a 50% stake in the company. 
The price action in Trump Media shares has been detached from the company's fundamentals for some time. During Trump&#8217;s 2024 presidential campaign, the stock moved up and down alongside&nbsp;Trump&#8217;s chances of reelection. Now the stock appears to be moving alongside Trump&#8217;s approval ratings. 
Trump&#8217;s approval ratings have fallen in recent months related to tariff uncertainty. Trump had approximately 47% approval when he took office in January, but Reuters reported his approval ratings had fallen to 43% as of last week.
It&#8217;s worth noting that Trump said in a Truth Social post Wednesday morning shortly after the market opened that &#8220;this is a great time to buy.&#8221; He included the ticker symbol for Trump Media in the <a href="https://truthsocial.com/@realDonaldTrump/posts/114308272725981913">post</a>. 
DJT Price Action: <a href="http://benzinga.com/quote/djt">Trump Media shares</a> closed Wednesday up 21.67% at $20.27. The stock was up another 5.82% after hours, trading at $21.45 at the time of publication, per <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/government/regulations/25/04/44723376/goldman-sachs-scraps-recession-call-after-trumps-surprise-tariff-pause-as-wall-street-marks-strongest-day-since-2008">Goldman Sachs Scraps Recession Call After Trump&#8217;s Surprise Tariff Pause As Wall Street Marks Strongest Day Since 2008</a></li>
</ul>
Photo: Shutterstock.

Comments

Zhengye Biotechnology

Zhengye Biotechnology (ZYBT) Opciones

No option chain data available. Please try again later

Noticias

SOCIO/CONTRIBUIDOR

BENZINGA GLOBAL